Insider Purchases: Inside the Buy

Tag: SummitTherapeutics

A biotech battlefield. In the foreground, a determined biotech researcher carries a glowing dual-target antibody labeled

June 5, 2026

🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown

Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.

Read entire article

Tags: Baker Brothers, BiotechStocks, buy or sell SMMT, cancer research, FDA approval, featured-insiders, FUNanc1al, FunStock, GARP, healthcare investing, hub-insiders, immunotherapy, insider buying, InsiderBuying, ivonescimab, Keytruda, lung cancer, oncology stocks, PDUFA, risks buying SMMT, Robert Duggan, short squeeze, ShortSqueeze, SMMT, Summit Therapeutics, SummitTherapeutics, ValueInvesting, why buy SMMT

Your cart

Insider Purchases: Inside the Buy

Tag: SummitTherapeutics

June 5, 2026

🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown

Quick links

Contact us

About us

Follow us